NCT00374660已完成1 期
Phase I-II Clinical and Pharmacokinetic Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 63
- 主要终点
- Hormone Refractory Prostate Cancer (HRPC) Cohort: Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and RECIST criteria.
研究概览
简要总结
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent obtained prior to initiation of any study-specific procedures and treatment.
- •Malignant solid tumor confirmed by a biopsy sample.
- •Pancreatic, endometrial, gastric, and hepatocellular cancer patients that have exhausted standard treatment options.
- •Measurable disease according to RECIST.
- •18 years of age or older.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-
- •Life expectancy greater than 3 months.
- •Previous anticancer treatment must be discontinued at least 4 weeks prior to first dose of study treatment (6 weeks for mitomycin C, 8 weeks for bicalutamide).
- •Patients of reproductive age must be using effective contraceptive methods.
- •Negative pregnancy test for patients of reproductive potential.
排除标准
- •Prior therapy with irofulven or oxaliplatin.
- •Patients who have had radiation therapy to more than 30% of the bone marrow prior to entry into the study.
- •Prior chemotherapy with nitrosoureas or high dose carboplatin (AUC > 6), prior mitomycin C cumulative dose greater than or equal to 25 mg/m², prior bone marrow transplant or intensive chemotherapy with stem cell support.
- •Presence of any serious concomitant systemic disorders incompatible with the study (e.g., uncontrolled congestive heart failure, active infection).
- •Any previous history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry, unless the active malignancy can be unmistakably identified by evidence such as recent biopsies or tumor specific markers.
- •Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry.
- •Pregnant or lactating patients or any patient with childbearing potential not using adequate contraception.
- •Patients with retinopathy or significant visual impairment not correctable by refractory lens will be enrolled on a case by case basis according to the expected benefit ratio, taking into account the malignant disease and the existence of an objective decreased visual acuity and its degree.
- •Please note: There are additional criteria that must be met in order to be eligible for this study.
研究组 & 干预措施
1
Experimental
干预措施: Oxaliplatin (Drug)
1
Experimental
干预措施: Irofulven (Drug)
结局指标
主要结局
Hormone Refractory Prostate Cancer (HRPC) Cohort: Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and RECIST criteria.
时间窗: Every 8 weeks until progression.
Confirmed response rate: Hepatocellular Cancer (HCC) Cohort: Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
时间窗: Every 8 weeks until progression.
次要结局
- Efficacy: HCC cohort - PFS (RECIST); overall survival(Every 8 weeks until progression.)
- Efficacy: HRPC Cohort: confirmed response rate according to RECIST; progression-free survival (PFS) for progression according to RECIST; new bone lesions or skeletal events; PFS according to PSA progression; overall survival.(Every 8 weeks until progression.)
研究者
相似试验
已完成
1 期
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C MutationNeoplasmsAdvanced Solid TumorsColorectal CancerNon-small Cell Lung CancerNCT04006301Janssen Research & Development, LLC10
已完成
1 期
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36
已完成
1 期
Study of RP-3500, Camonsertib, in Advanced Solid TumorsAdvanced Solid TumorNCT04497116Repare Therapeutics276
已完成
1 期
Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced GlioblastomaGlioblastomaNCT02728349Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd26
终止
1 期
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory CancerNeoplasmsNCT00547261Sanofi6